Skip to main content


Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs


P-glycoprotein (P-gp), a well known efflux transporter in the blood brain barrier inhibits the uptake of substrate drugs into brain. The main aim of this study is to evaluate the effect of natural product based P-gp inhibitors on brain penetration of various CNS drugs which are P-gp substrates. In this study, we have evaluated the inhibitory effects of natural bioflavonoids (quercetin and silymarin) on P-gp by using digoxin and quinidine as model P-gp model substrate drugs. In vitro inhibitory effects were evaluated in Caco-2 cell lines using digoxin as a model drug and in vivo P-gp inhibiting effect was evaluated in mice model using quinidine as model drug. The accumulation and bidirectional transport of digoxin in Caco-2 cells was determined in presence and absence of quercetin and silymarin. Elacridar was used as standard P-gp inhibitor and used to compare the inhibitory effects of test compounds. The apical to basolateral transport of digoxin was increased where as basolateral to apical transport of digoxin was decreased in concentration dependent manner in the presence of elacridar, quercetin and silymarin. After intravenous administration of P-gp inhibitors, brain levels of quinidine were estimated using LC-MS method. Increased brain uptake was observed with quercetin (2.5-fold) and silymarin (3.5-fold). Though the brain penetration potential of P-gp substrates was lower than that observed in elacridar, both quercetin and silymarin improved plasma quinidine levels. Caco-2 permeability studies and brain uptake indicate that both quercetin and silymarin can inhibit P-gp mediated efflux of drug into brain. Our results suggest that both silymarin and quercetin could potentially increase the brain distribution of co-administered drugs that are P-gp substrates.


P-gp is an established factor in altering the pharmacokinetics of several drugs. Based on the studies of P-gp knockout mice and from the investigations of the effect of P-gp inhibitors on normal rodents and humans, it is known that P-gp is capable of decreasing the oral bioavailability and brain distribution of drugs that are substrates of the P-gp efflux pump (Gallo et al. 2003). Presence of P-gp expression at the apical surfaces of brain capillary endothelial cells and gut enterocytes has been determined to limit the penetration of P-gp substrates such as ivermectin and cyclosporin A in to the respective organs (Kwei et al. 1999). Later studies have revealed that P-gp is also present in many normal tissues including liver, kidney etc. (Cordon-Cardo et al. 1990). The generation of mice with disrupted P-gp knock out (KO) genes confirmed the significant protective pharmacological function of P-gp in the Blood Brain Barrier (BBB) (Schinkel et al. 1994, 1996). Entry of several drugs including vinblastine, cyclosporine A, digoxin, dexamethasone into the brain has been regulated by P-gp (Schinkel et al. 1995). In P-gp knockout mice, the penetration of vinblastine into the brain was 7–46 folds higher when compared with wild type control (Van Asperen et al. 1996), encompasing the role of P-gp in preventing the entry of its substrates into the brain. A fraction of epileptic patients do not respond to commonly prescribed antiepileptic drugs because of limited delivery to the brain. Studies suggest that the failure is because of over expression of ATP-driven efflux pumps at the BBB (Löscher and Potschka 2005). Escitalopram, a P-gp substrate, brain delivery was increased by P-gp inhibition using cyclosporin and verapamil thereby resulted in enhanced antidepressant activity with threefold increased brain concentration (O’Brien et al. 2013). Elacridar is a selective inhibitor for both P-gp and breast cancer resistance protein (BCRP) (Hyafil et al. 1993). There are number of drugs which have been reported as dual substrates for P-gp and BCRP (de Vries et al. 2007). For the drugs to act in the CNS, sufficient drug delivery is pre requisite. So, the evaluation of drug candidate susceptibility for P-gp efflux is a crucial step in the development of novel therapeutics particularly in targeting CNS. Silymarin, a bioflavonoid, is used for more than 2000 years to treat a range of liver and gallbladder disorders, including hepatitis, cirrhosis, and jaundice, and to protect the liver against poisoning from chemical and environmental toxins, including snake bites, insect stings, mushroom poisoning, and alcohol. The major active component is silibinin/silybin, which is hepatoprotective and possesses P-gp inhibiting property (Gazak et al. 2007). Silymarin potentiated the doxorubicin cytotoxicity in P-gp positive cells by inhibiting P-gp ATPase activity (Zhang and Morris 2003b). Similar results were observed in another study where silymarin in combination with biochanin A (an iso flavone from red clover extract) potentially increased the daunomycin cytotoxicity and decreased the daunomycin efflux in resistant breast cancer cell line, MCF-7 ADR (Chung et al. 2005). The same combination increased the accumulation of digoxin and vinblastine in intestinal Caco-2 cells in a concentration dependent manner (Zhang and Morris 2003a).

Quercetin, another flavonoid, has multiple biological actions such as antioxidant, antiulcer, antiallergic and anticancer. Currently, it is in clinical trials for the treatment of cancer and may be a promising drug of choice in future (Lakhanpal and Rai 2007). Quercetin decreased the resistance and increased the sensitivity of vinblastine and paclitaxel dose dependently in KBVI cells (human cervical carcinoma) which have P-gp expression (Limtrakul et al. 2005). Cell lines of human pancreatic carcinoma EPP85-181RDB (resistant to daunorubicin) and EPP85-181P (sensitive to daunorubicin) were treated with quercetin and found that quercetin altered the function of P-gp and decreased the expression of ABCB1 in EPP85-181RDB cell line. Through these findings quercetin was considered as potential modulator of P-gp (Borska et al. 2010). P-gp substrates digoxin and quinidine were selected based on the physicochemical properties. Digoxin is a lipophilic drug (logP = 2.37) with low permeability (Caco-2, Papp 1.1 × 10−6 cm/s) and quinidine is another lipophilic drug with high permeablity (Caco-2 Papp 20.4 × 10−6 cm/s) (Collett et al. 2004). The main aim of this study is to evaluate the effect of natural product based P-gp inhibitors on brain penetration of various CNS drugs which are P-gp substrates. Pharmacological inhibition of these efflux transporters prevents the inadequate distribution of drugs to the brain.



Caco-2 cells were procured from ATCC, USA. Transwell 24-well inserts were procured from Corning (USA), Dulbecco’s modified eagles medium (DMEM) was from Gibco, 96 well plate, hydrophilic solvinert plates were purchased from Millipore, USA. Digoxin, quinidine, quercetin, silymarin and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (USA) and all other chemicals were of HPLC grade.

Cell culture

Caco-2 cells were seeded in transwell poly carbonate inserts (6 well, 0.4 µm pore size, Corning co-star Co.) at 70,000 cells per insert on the day of seeding. Cells were cultured in DMEM supplemented with 10 % fetal bovine serum and 1 % non essential amino acids (Gibco). All the cells were incubated at 37 °C in a humidified atmosphere with 5 % CO2 and 95 % air. For uptake studies, Caco-2 cells were seeded on to 0.7 cm2 dishes at a density of approximately 70,000 cells per dish and used for experiment. On the day of 21 TEER (Tran’s epithelial electrical resistance) value was measured using Epithelial Volt ohmmeter (world precision instruments) and observed TEER value as more than 500 Ω cm2 that reflects confluent monolayer with tight junctions.


Male C57 mice weighing 30–35 g and of 6–8 weeks old were taken and the animal experiments were conducted in the animal research facility of Syngene International limited, Bengaluru, India. Animals were kept under a 12 h light/dark cycle with free access to water and food (Kumar et al. 2014). Animal study protocols were approved by the Syngene International organisational animal ethics committee, Bengaluru, India.


Dose volumes (5 mL/kg) of drugs were administered by i.v. route via tail vein injection. Quinidine formulation was prepared using 10 % Dimethylacetamide (DMAC), 40 % Polyethyleneglycol (PEG-400), 20 % Water and 30 % of Hydroxypropyl β-cyclodextrin (HPβCD). The elacridar formulation contained 10 % DMAC, 40 % PEG-400, 30 % HPβCD and 20 % water, quercetin and silymarin formulations were prepared using 2 % N-methyl-2-pyrolidone, 10 % ethanol, 30 % Polyethylene glycol 200 (PEG 200) and 58 % saline.

Transport study

Transport experiments using Caco-2 cell monolayers were performed, Caco-2 cell monolayer’s with TEER value higher than 500 cm2 were washed with transport buffer (HBSS) containing 10 mM HEPES buffer. Transport buffer containing quercetin and silymarin (50 and 100 µM) solution was incubated for 30 min in apical chamber for apical to basal (AP to BL) assay and basal chamber for basal to apical (BL to AP) assay in a single plate. All solutions were prepared in dimethylsulphoxide (DMSO). The final concentration of DMSO in the wells was less than 0.1 %. After incubation, wells were washed with transport buffer. Transport buffer containing digoxin 10 µM, elacridar 5 µM + digoxin 10 µM, Silymarin 50 µM + digoxin 10 µM, Silymarin 100 µM + digoxin 10 µM, Quercetin 50 µM + digoxin 10 µM, Quercetin 100 µM + digoxin 10 µM was added to apical chamber for apical to basolateral assay and basal chamber for basolateral to apical assay, rest added with 2 % bovine serum albumin (BSA) solution for non-specific interaction to the assay. Samples (200 µL) were taken from the receiver side at both chambers for analysis after incubating the cell monolayer’s at 37 °C for 30, 60 and 90 min and replaced with fresh transport buffer. The Caco-2 cell viability was studied in presence of silymarin and quercetin and found that the cell viability was not affected.

Brain penetration study of elacridar and quinidine

Mice were divided into two groups (n = 4). One group dosed with elacridar (5 mg/kg) i.v. 30 min prior to the dosing of quinidine (5 mg/kg) and the other group dosed with quinidine alone. Blood and brain samples were collected at 0.5, 1, 3, 5 and 7 h post dose of probe substrate quinidine. Plasma and brain samples were collected and stored at −80 °C until analysis.

Brain penetration study of silymarin and quercetin with quinidine

Mice were divided into three groups (n = 3–4). First group dosed with silymarin (20 mg/kg) i.v. 30 min prior to the dosing of quinidine (5 mg/kg). Second group dosed with quercetin (20 mg/kg) i.v. 30 min prior to the dosing of probe substrate quinidine and the other group dosed with probe substrate quinidine alone. Blood and brain samples were collected at 0.5, 1, 3, 5 and 7 h post dose of probe substrate. Blood was collected from mice under mild anaesthesia via tail vein and collected blood was centrifuged at 5000 rpm to separate plasma.

Sample preparation

After sacrificing the mice at different time points, brain was collected homogenised at 5× concentration with phosphate buffered saline using Bullet blender. Fifty µL of brain homogenate or plasma and 200 µL of internal standard (IS) in vehicle (70 % acetonitrile and 30 % water) were mixed in a 96-well hydrophilic solvinert plate. The acetonitrile mixtures were vortexed and centrifuged at 10,000 rpm for 10 min. Supernatant was collected in a 96 well plate and analysed by liquid chromatography with mass spectroscopy (LC-MS, QTRAP ABSCIEX API 4000).

LC-MS analysis

Standard curves were prepared by spiking a known concentration of quinidine into blank matrix and then processed according to the procedures described previously for each sample. Analysis was carried out using 4000 QTRAP LC/MS/MS system with triple Quadruple mass spectrometer (AB SCIEX) equipped with an electron spray ionisation (ESI). The mass spectrometer was operated in the ESI positive ion mode and detection of ions were performed in the multiple reaction monitoring (MRM) mode. The system was run in a gradient mode and flow rate was set at 0.67 mL/min for runtime of 2.5 min (Table 1). The standard curves were linear and assay accuracy was found to be between 85 and 115 %.

Table 1 LC-MS conditions followed to analyze quinidine and digoxin in plasma and cell culture samples

Pharmacokinetic analysis

Pharmacokinetic parameters (Cmax, t1/2, AUC, Tmax) were determined based on non compartmental approach using Phoenix winNonlin (Version 6.3).

Statistical analysis

The data obtained in this study were expressed as the mean of replicate determinations (n = 3–4) plus or minus the standard error mean (SEM). Statistical comparisons were made using T-test and one way analysis of variance (ANOVA). The intergroup variations were measured by Bonferroni’s Mulptiple comparison test using the software Graph Pad Prism 5.0.


Effect of elacridar on the transport of P-gp substrate digoxin across Caco-2 monolayers

Elacridar was standardised on the transport of digoxin across Caco-2 cell monolayer’s in both apical to basolateral and basolateral to apical directions. As shown in Table 2, the apparent permeability coefficient for basolateral to apical transport of digoxin (PappB–A: 1.8 × 10−6 cm/s) was higher than apical to basolateral (PappA–B: 5.18 × 10−8 cm/s) with a mean transport ratio (PappB–A/PappA–B) of 34.77, which shows the involvement of P-gp mediated efflux of digoxin in these cells. In presence of 5 µM elacridar (Table 2), the digoxin efflux of PappA–B was significantly increased (from 5.18 × 10−8 to 1.52 × 10−7 cm/s) whereas the PappB–A was significantly decreased (from: 1.8 × 10−6 to 2.78 × 10−7 cm/s) resulting into a mean transport ratio of 1.83 (Table 2). All these results suggest that elacridar inhibited P-gp mediated cellular efflux and thus increase the apical to basolateral transport of digoxin and decrease the basolateral to apical transport of digoxin, which indicates that elacridar as a complete P-gp inhibitor (Table 2; Fig. 1).

Table 2 Efflux ratio for digoxin in presence and absence of elacridar in the Caco-2 cell lines
Fig. 1

In vitro Caco-2 based P-gp inhibition study: a Efflux ratio of Digoxin and Digoxin with Elacridar, b Efflux ratio of Digoxin 10 µM alone, Digoxin in presence of Quercetin and Silymarin (50 and 100 µM). Each data point was represented as mean ± SEM (n = 3–4). *p < 0.05; **p < 0.01 and ***p < 0.001 vs Quinidine alone groups. (D digoxin, E elacridar, Qr quercetin, S silymarin)

Effect of silymarin and quercetin on the transport of P-gp substrate digoxin across Caco-2 monolayers

As shown in Table 3, the apparent permeability coefficient for basolateral to apical transport of digoxin (PappB–A: 1.8 × 10−6 cm/s) was higher than apical to basolateral (PappA–B: 5.18 × 10−8 cm/s) with a mean transport ratio (PappB–A/PappA–B) of 34.77, which shows the involvement of P-gp mediated efflux of digoxin in these cells. In presence of 50 µM quercetin, the PappA–B was slightly increased (from 5.18 × 10−8 to 5.93 × 10−8 cm/s) whereas the PappB–A was slightly decreased (from 1.8 × 10−6 to 1.23 × 10−6 cm/s) resulting a mean transport ratio of 20.79. In presence of 100 µM quercetin (Table 3), the PappA–B was increased (from 5.18 × 10−8 to 1.04 × 10−7 cm/s) whereas the PappB–A was decreased (from 1.8 × 10−6 to 1.21 × 10−6 cm/s) resulting a mean transport ratio of 11.70. In presence of 50 µM silymarin, the PappA–B was increased (from 5.18 × 10−8 to 5.51 × 10−8 cm/s) whereas the PappB–A was decreased (from 1.8 × 10−6 to 1.63 × 10−6 cm/s) resulting in a mean transport ratio of 29.69 In presence of 100 µM silymarin, the PappA–B was increased (from 5.18 × 10−8 to 6.64 × 10−8 cm/s) whereas the PappB–A was decreased (from 1.8 × 10−6 to 1.42 × 10−6 cm/s) resulting an mean transport ratio of 21.35 (Table 3). The Caco-2 permeability results indicate that both silymarin and quercetin can inhibit P-gp mediated cellular efflux and thus increase the AP to BL transport of digoxin and decrease the BL to AP transport of digoxin. Quercetin had stronger effects than silymarin when used at the same concentration, but neither of the flavonoids blocked P-gp completely at the tested concentrations of quercetin and silymarin at 50 and 100 µM respectively. Both silymarin and quercetin showed concentration dependent effect on digoxin transport as shown in the Table 3 and Fig. 1.

Table 3 Efflux ratio for digoxin in presence and absence of silymarin and quercetin in the Caco-2 cell lines

Effect of elacridar on plasma and brain pharmacokinetics and brain penetration of quinidine

Results of in vitro study motivated us to evaluate the efficacy in vivo. Mouse mean plasma concentration versus time of i.v. dosed quinidine (5 mg/kg), in the presence and absence of elacridar (5 mg/kg i.v. 0.5 h pre-treatment) were recorded. Pre-treatment of elacridar showed no significant difference in the plasma profile of quinidine, but a trend of increased t1/2 was observed whereas pre-treatment with elacridar resulted in significant difference in the brain profile of quinidine concentration with an increased Cmax and brain area under the curve (AUC) 0–7h (Table 4).

Table 4 Mean plasma and brain pharmacokinetics parameters of quinidine in the presence and absence of elacridar after i.v. administration in mice

Effect of silymarin and quercetin on plasma and brain pharmacokinetics and brain penetration of quinidine

Pre-treatment of silymarin showed significant improvement in plasma pharmacokinetic profile as well as brain penetration of quinidine with increased t1/2, Cmax and AUC. Pre-treatment of silymarin resulted in a maximum 3.5-folds increase in Kp, brain of quinidine. Pre-treatment of silymarin increased (AUC) 0–7h B/P by twofolds for quinidine (Fig. 2; Table 5). However, pre-treatment of quercetin showed no significant difference in plasma profile, but a trend of increased t1/2 and Cmax was observed indicating an increased brain profile of quinidine with a trend of increased t1/2, Cmax and AUC. In contrast, pre-treatment with quercetin resulted in 2.5-folds increase in Kp and brain (AUC) 0–7h B/P by twofold of quinidine. The respective representation of chromatograms depicting concentration of quinidine, quinidine + silymarin and quinidine + quercetin in both plasma and brain are mentioned in Fig. 3.

Fig. 2

In vivo P-gp inhibition study: a Mean plasma concentration, b Mean brain concentration, c Plasma AUC. d Brain AUC and e Brain to plasma ratio of Quinidine when combined with Quercetin and Silymarin. Each data point was represented as mean ± SEM (n = 3–4). *p < 0.05; **p < .0.01 and ***p < 0.001 versus Quinidine alone groups

Table 5 Mean plasma and brain pharmacokinetic parameters of quinidine in the presence and absence of silymarin and quercetin (10 mg/kg) after i.v. administration in mice
Fig. 3

Representative LC-MS chromatograms of Quinidine, a plasma concentration of Quinidine + Silymarin; b plasma concentration of Quinidine + Quercetin; c brain concentrations of Quinidine + Silymarin, and d brain concentrations of Quinidine + Quercetin after 2 h of administration. The left lane peaks are quinidine alone and right lane in presence of Silymarin/Quercetin. The shift in retention time in respective chromatograms indicates significant increase in the area under the curve in comparison to the quinidine alone peaks indicating effective P-gp inhibition in presence of drug treatment


Delivery to brain has ever been a major hurdle by virtue of blood brain barrier (BBB) that shields the brain from other body organs. Treatment of CNS disorders like epilepsy, Alzheimer and brain tumors poses a great challenge due to sub effective concentration of drug reaching the target site. To achieve this goal, the researchers are working on novel strategies to improve the BBB distribution of drugs in glioblastoma patients. The present study aims at improvement of brain delivery of quinidine, an FDA approved drug used for cerebral malaria and a well known P-gp substrate, by using natural flavonoids quercetin and silymarin, which are well known P-gp inhibitors. Several lines of evidences have reported the role of both quercetin and silymarin as intestinal P-gp inhibitors. Significant improvement of relative bioavailability was observed in study performed to enhance the oral bioavailability of paclitaxel and its formulation (Taxol) using silymarin and quercetin as P-gp inhibitor (Park et al. 2012; Choi et al. 2004). In consistent with the findings, in present study we used silymarin and quercetin to inhibit the P-gp at the BBB. The presence of P-gp efflux transporter at the BBB may restrict the entry of several P-gp substrates into the brain. The in vivo brain-to-plasma concentration ratio of vincristine in ddY mice was decreased by co-administration of 0.1 mg/kg quercetin, but increased by 1.0 mg/kg quercetin (Mitsunaga et al. 2000). In current study, we used different drugs/agents either as P-gp substrates (quinidine and digoxin) and P-gp inhibitors (elacridar, silymarin and quercetin) to evaluate the role of P-gp in brain distribution of drugs.

The model was established with standard P-gp inhibitor elacridar and was used to analyze the brain penetration of quinidine. In vitro Caco-2 cell line based permeability studies were performed by using digoxin as model P-gp substrate. The model P-gp subtrates, quinidine (high permeabililty) and digoxin (low permeability) were selected, which are lipophilic drugs and having Caco-2 Papp 20.4 × 10−6 and 1.1 × 10−6 cm/s, respectively (Schinkel et al. 1995). The effect of in vivo P-gp inhibition of elacridar, silymarin and quercetin was calculated in terms of the increase in Kpbrain and brain to plasma AUC ratio in mice model. The in vitro P-gp inhibition was studied as efflux ratio of probe substrates in presence of selected inhibitors in Caco-2 cell line. Further, several studies had shown that P-gp efflux transporter contributes to the efflux of digoxin and quinidine across the BBB (Mayer et al. 1997).

We estimated P-gp inhibition of quercetin and silymarin using Caco-2 permeability assay and compared those inhibitory effects with standard strong P-gp inhibitor elacridar. Both quercetin and silymarin produced concentration dependent P-gp inhibitory effects on Caco-2 cell lines by increasing the apical to basolateral transport of digoxin. We observed a significant change in the transport of digoxin with both the selected test inhibitors at 50 and 100 µM concentrations for AP-to-BL as well as BL-to-AP transport. By using quercetin as a P-gp inhibitor similar type of results were published by Zhang et al. (Zhang and Morris 2003a). In our study, quercetin appears to be more potent than silymarin in terms of digoxin efflux ratio on Caco-2 cell lines. Kpbrain of P-gp substrate quinidine was measured at different time point’s i.e. 0.5, 1, 2, 4 and 7 h in mice in the presence of elacridar, quercetin and silymarin. At 1 h time point, the fold increase in Kpbrain of P-gp substrate quinidine was found to be 22.5 in presence of elacridar, 3.5 in the presence of silymarin and 2.5 in the presence of quercetin. These results suggest that Kpbrain values varied with time of measurement and distribution kinetics of the compound. A single time point measurement could mislead the evaluation of brain penetration of P-gp substrate. Therefore, in addition to Kpbrain we also determined the brain to plasma AUC ratio (B/P).

Quinidine showed a 3.5 and 2.5 folds increase in B/P ratio in combination with silymarin and quercetin, respectively in mice. Similar results were published by Xiao et al. (2012) and Batrakova et al. (2001). In presence of elacridar in mice, the B/P ratio of quinidine was increased by 22.5 fold over the control animals. Similarly, Kallem et al. (2012) reported a 38 fold increase in the B/P of quinidine in mice. The greater improvement of quinidine B/P with elacridar was compared with that of silymarin and quercetin. It was known that compounds with B/P greater than two in mdr1a/1b KO over the wild type mice (WT) are P-gp substrates (Liu et al. 2009). In the present study, animals treated with elacridar, silymarin and quercetin also resulted in B/P ratio greater than two which confirms that selected inhibitors have significant impact on the brain distribution of P-substrate drugs like quinidine. Moreover, findings of Youdim et al., prove that quercetin is able to effectively traverse the BBB based on the rate of uptake in in vitro (ECV304/C6 coculture) and in situ (rat, cerebral hemispheres) models. Quercetin showed measurable in vitro and in situ BBB permeability. Furthermore, quercetin showed measurable quantities inside MDCK-MDR1 and immortalized rat brain endothelial cells (RBE4) proving the fact that it is able to bypass the over expressed efflux transporters, which is in line with our in vivo findings (Ishisaka et al. 2011). In another study Mitsunaga et al. (2000) showed the increase in uptake of [3H]vincristine across BBB upon treatment with 50 μM quercetin in vitro in cultured mouse brain capillary endothelial cells (MBEC4) and by 1.0 mg/kg quercetin in vivo (ddY mice) which further conceptually proves our hypothesis. We also examined the effect of silymarin and quercetin on the pharmacokinetics of quinidine in mice and found an increase in half life and AUC compared with quinidine control.

Our study described that co-administration of silymarin and quercetin can improve drug delivery of P-gp substrate drugs in several brain disorders including glioblastoma and epilepsy. The P-gp inhibitory effects of quercetin and silymarin can be beneficial to deliver the drugs into brain where P-gp mediated efflux is the major barrier. Both, quercetin and silymarin have numerous pharmacological activities and can synergise with many of such drugs that face the problem of poor brain penetration.


We conclude that concurrent use of quercetin and silymarin is safe in combination with the drugs which are P-gp substrates, to increase brain distribution. These compounds possess multiple pharmacological actions like anti-oxidant, anti-cancer, and anti-fibrotic activities, thus can be used synergistically for efficacious therapy with other conventional treatment regimens. Besides, the anti-oxidant nature of these drugs will nullify the oxidative stress produced by the P-gp substrate drugs like doxorubicin etc which further adds to the significance of the use of anti-oxidants of plant origin.


  1. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF (2001) Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharm Exp Ther 296(2):551–557

  2. Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P (2010) Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 15(2):857–870

  3. Choi JS, Jo BW, Kim YC (2004) Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 57(2):313–318

  4. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ (2005) Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 28(7):823–828

  5. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G (2004) Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a (−/−) mice in vivo. Pharm Res 21(5):819–826

  6. Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38(9):1277–1287

  7. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13(21):6440–6449

  8. Gallo JM, Li S, Guo P, Reed K, Ma J (2003) The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 63(16):5114–5117

  9. Gazak R, Walterová D, Kren V (2007) Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14(3):315–338

  10. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53(19):4595–4602

  11. Ishisaka A, Ichikawa S, Sakakibara H, Piskula MK, Nakamura T, Kato Y, Ito M, Miyamoto K, Tsuji A, Kawai Y, Terao J (2011) Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. Free Radic Biol Med 51(7):1329–1336

  12. Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S (2012) A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier. Drug Metab Lett 6(2):134–144

  13. Kumar GS, Kulkarni A, Khurana A, Kaur J, Tikoo K (2014) Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy. Chem Biol Interact 223C:125–133

  14. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, Pippert TR, Umbenhauer DR (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27(5):581–587

  15. Lakhanpal P, Rai DK (2007) Quercetin: a versatile flavonoid. IJMU 2(2):22–37

  16. Limtrakul P, Khantamat O, Pintha K (2005) Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 17(1):86–95

  17. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37(4):787–793

  18. Löscher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6(8):591–602

  19. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100(10):2430–2436

  20. Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H, Sawada Y (2000) Effect of bioflavonoids on vincristine transport across blood–brain barrier. Eur J Pharmacol 395(3):193–201

  21. O’Brien FE, O’Connor RM, Clarke G, Dinan TG, Griffin BT, Cryan JF (2013) P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology 38(11):2209–2219

  22. Park JH, Park JH, Hur HJ, Woo JS, Lee HJ (2012) Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur J Pharm Sci 45(3):296–301

  23. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77(4):491–502

  24. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96(4):1698–1705

  25. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97(11):2517–2524

  26. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O (1996) Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 88(14):994–999

  27. Xiao G, Black C, Hetu G, Sands E, Wang J, Caputo R, Rohde E, Gan LS (2012) Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos 40(4):779–787

  28. Zhang S, Morris ME (2003a) Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 20(8):1184–1191

  29. Zhang S, Morris ME (2003b) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304(3):1258–1267

Download references

Authors’ contributions

CG, DRR, AK and SB designed the study, participated in interpretation of results and wrote the manuscript. DRR, RR, VSSR, and MM performed data acquisition and analysis. CG approved the final manuscript. All authors read and approved the final manuscript.


The authors are thankful to the project director NIPER-Hyderabad for the support. Authors would like to acknowledge Syngene International Ltd, Bangalore, and Ministry of Chemicals and Fertilizers, Govt. of India for the funding.

Competing interests

The authors declare that they have no competing interests.

Author information

Correspondence to Chandraiah Godugu.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ravikumar Reddy, D., Khurana, A., Bale, S. et al. Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. SpringerPlus 5, 1618 (2016).

Download citation


  • Quercetin
  • Digoxin
  • Quinidine
  • Silymarin
  • Breast Cancer Resistance Protein